Opinion
Video
Navigating EoE Treatments: An Overview of Options and Progress
Elizabeth Spencer, MD, discusses various treatments for eosinophilic esophagitis (EoE) across age groups, highlighting the role of dietary modifications, proton pump inhibitors, swallowed corticosteroids, and monoclonal antibodies.
This is a video synopsis/summary of an Insights involving Elizabeth Spencer, MD.
Spencer underscores the evolving landscape of FDA-approved therapies for eosinophilic esophagitis (EoE), instilling hope for effective solutions and emphasizing caregivers’ need for such optimism. She delineates treatment categories, starting with dietary elimination, showcasing the efficacy of eliminating common allergens like dairy, wheat, eggs, soy, peanuts, and tree nuts. She explains that gradual eliminations from 6 to 1 food group impact the success rate, emphasizing the social challenges these restrictions pose to children.
The next treatment involves proton pump inhibitors to manage acid reflux, attributing confusion between EoE and reflux in the past but now considering them under a single umbrella. Swallowed corticosteroids represent another effective therapy, showing a 60% to 90% response rate but raising concerns about potential long-term impacts on growth and adrenal function.
Monoclonal antibodies offer promising results for EoE, inducing histologic remission in a significant percentage of patients and currently undergoing FDA review for younger age groups. Spencer notes their broader applications in treating various allergic conditions, highlighting their potential as a single medication targeting multiple ailments.
Additionally, ongoing research explores monoclonal antibodies targeting specific immune system components, aiming to alleviate EoE symptoms and restore patients’ well-being. Spencer concludes by defining monoclonal antibodies and their role in restoring immune balance, representing a potential breakthrough in EoE treatment.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
